Barclays Raises Kodiak Sciences Price Target to $7.00, Maintains 'Underweight' Rating

Barclays analyst Gena Wang has raised Kodiak Sciences' price target to $7.00, a 75% increase from $4.00. The rating remains 'Underweight', suggesting the stock is expected to underperform the market. The updated valuation reflects anticipated market conditions and company projections. Investors should take note of this updated analyst opinion when assessing investment strategies.

Kodiak Sciences (NASDAQ: KOD) reported its second-quarter (Q2) 2025 financial results, which included a net loss of $54.3 million, missing analyst estimates. Despite the loss, the company's cash position remains strong, with $104.2 million in reserves, supporting operations through 2026 [1].

Notable business highlights include the completion of enrollment in the Phase 3 GLOW2 trial for Tarcocimab in patients with diabetic retinopathy. Additionally, the company's shares saw a significant increase following an upgrade from Jefferies, with the firm raising its price target to $20 from $6 [2].

The Q2 net loss was primarily driven by increased research and development (R&D) expenses of $42.8 million, up from $32.5 million in the same period last year. This increase is attributed to ongoing clinical studies for Tarcocimab, KSI-501, and KSI-101 [1].

Kodiak Sciences' cash position at $104.2 million is expected to support operations into 2026. The company also reported that general and administrative (G&A) expenses decreased to $12.8 million, down from $15.5 million in the previous quarter [1].

The company's shares soared after Jefferies upgraded its rating and raised its price target. Analysts at Jefferies noted the progress of Kodiak Sciences' clinical pipeline and the potential of Tarcocimab in treating retinal diseases [2].

Kodiak Sciences continues to advance its clinical pipeline, with multiple Phase 3 readouts expected between the first quarter of 2026 and the first quarter of 2027. The company's KSI-101 Phase 1b data in MESI patients showed rapid anatomical improvements and over 90% of patients achieving dryness by week 8 [1].

In related news, Barclays analyst Gena Wang has raised Kodiak Sciences' price target to $7.00, a 75% increase from $4.00. The rating remains 'Underweight', suggesting the stock is expected to underperform the market. The updated valuation reflects anticipated market conditions and company projections. Investors should take note of this updated analyst opinion when assessing investment strategies [3].

References:
[1] https://www.stocktitan.net/news/KOD/kodiak-sciences-announces-recent-business-highlights-and-second-3gycq350yqmy.html
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_PLX21058D:0-kodiak-sciences-q2-net-loss-misses-estimates/
[3] https://www.ainvest.com/news/barclays-analyst-raises-kodiak-sciences-price-target/